Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaglenastat + Nivolumab in Advanced Solid Tumors
NCT02771626Phase 2Terminated
- Sponsor
- Calithera Biosciences
- Start
- Aug 2016
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of telaglenastat in clear cell renal cell carcinoma (ccRCC), melanoma and non-small cell lung cancer (NSCLC) (6 arms), sponsored by Calithera Biosciences. Primary endpoints: Treatment-Emergent Adverse Events, Clinically Significant Treatment-Emergent Values in Hematology, Serum Chemistry Panel, Vital Signs or Weight and 2 more. Started Aug 2016; status: terminated.
02
Drugs
telaglenastat
03
Conditions
clear cell renal cell carcinoma (ccRCC)melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02771626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02771626.